Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
NCT00020475 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020475 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye |
| Official title | Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extraocular Extension Melanoma, Recurrent Intraocular Melanoma |
| Intervention type | Drug |
| Interventions | gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51 |
| Start date | Feb 1, 2001 |
| Completion | Mar 1, 2007 |
| First posted | Mar 6, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: